公开(公告)号：US20130209355A1

公开(公告)日：2013-08-15

申请号：US13702857

申请日：2011-06-08

Applicant: Michel De Weers ,  Tim Walseth ,  Jan Van De Winkel ,  Tom Vink ,  Paul Parren

Inventor： Michel De Weers ,  Tim Walseth ,  Jan Van De Winkel ,  Tom Vink ,  Paul Parren

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/76 ,  G01N33/573 ,  G01N2333/91148

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

Abstract translation: 公开了结合人CD38和相关的基于抗体的组合物和分子的分离的单克隆抗体。 还公开了包含抗体的药物组合物和使用抗体的治疗和诊断方法。

公开(公告)号：US09249226B2

公开(公告)日：2016-02-02

申请号：US13702857

申请日：2011-06-08

Applicant: Michel de Weers ,  Tim Walseth ,  Jan van de Winkel ,  Tom Vink ,  Paul Parren

Inventor： Michel de Weers ,  Tim Walseth ,  Jan van de Winkel ,  Tom Vink ,  Paul Parren

IPC: C07K16/30 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/76 ,  G01N33/573 ,  G01N2333/91148

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

Abstract translation: 公开了结合人CD38和相关的基于抗体的组合物和分子的分离的单克隆抗体。 还公开了包含抗体的药物组合物和使用抗体的治疗和诊断方法。

公开(公告)号：US20080114079A1

公开(公告)日：2008-05-15

申请号：US11652265

申请日：2007-01-10

Applicant: Frances E. Lund ,  Santiago Partida-Sanchez ,  Tim Walseth

Inventor： Frances E. Lund ,  Santiago Partida-Sanchez ,  Tim Walseth

IPC: A61K47/00 ,  C12N5/06 ,  C12Q1/02 ,  A61P9/00 ,  A61P1/00 ,  A61P19/00

CPC classification number: C07K14/705 ,  A61K31/365 ,  G01N33/6872 ,  G01N2500/04

Abstract: The present invention relates to methods and compositions for modulating ADPR-mediated migratory activity of cells through regulation of the TRPM2 cation channel. Such methods and compositions may be used for the treatment of disorders including, but not limited to, inflammation, ischemia, atherosclerosis, asthma, autoimmune disease, diabetes, arthritis, allergies, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages, monocytes and dendritic cells. The invention further relates to specific inhibition of TRPM2 by blocking the activity of ADPR. The invention also relates to drug screening assays designed to identify compounds that regulate TRPM2 and thereby also function to modulate ADPR-mediated cell migration. The invention is based on the discovery that, 8Br-ADPR, which specifically inhibits activation of TRPM2, acts to inhibit ADPR-mediated cell migration.

Abstract translation: 本发明涉及通过调节TRPM2阳离子通道调节ADPR介导的细胞迁移活性的方法和组合物。 这些方法和组合物可用于治疗疾病，包括但不限于炎症，缺血，动脉粥样硬化，哮喘，自身免疫性疾病，糖尿病，关节炎，过敏反应和移植排斥。 这样的细胞包括例如嗜中性粒细胞，淋巴细胞，嗜酸性粒细胞，巨噬细胞，单核细胞和树突状细胞。 本发明还涉及通过阻断ADPR的活性而对TRPM2的特异性抑制。 本发明还涉及设计用于鉴定调节TRPM2的化合物并由此也可用于调节ADPR介导的细胞迁移的药物筛选测定。 本发明基于以下发现：特异性抑制TRPM2激活的8Br-ADPR起抑制ADPR介导的细胞迁移的作用。